Atrion Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Athey Preston G, was filed 01 Dec 2023.
Atrion Corp: what insiders have been doing
This page follows insider dealings at Atrion Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Atrion Corp has had no insider filing for more than a year; the last one goes back to 21 August 2024.
Our records for Atrion Corp go back to 2006, with 12 purchases and 303 sales on the open market in total.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
- 6,394 shares@ US$460.00100.0% of flowcommon stockSEC:0001085535-24-000004:0
- 186 shares@ US$460.0049.7% of flowcommon stockSEC:0001920839-24-000002:0
- 2,678 shares@ US$460.00100.0% of flowcommon stockSEC:0001403233-24-000002:0
- 1,368 shares@ US$460.0075.4% of flowcommon stockSEC:0001700366-24-000002:0
- 118 shares@ US$460.00100.0% of flowcommon stockSEC:0001963160-24-000004:0
- 150,616 shares@ US$460.0093.8% of flowcommon stockSEC:0001221109-24-000002:0
- 55,500 shares@ US$460.0083.0% of flowcommon stockSEC:0001400964-24-000005:0
- 1,276.29 shares0common stockSEC:0001400964-24-000005:1
- 8,932 shares@ US$460.005.9% of flowcommon stockSEC:0001085535-24-000004:1
- 135,000 shares@ US$460.0089.5% of flowcommon stockSEC:0001085535-24-000004:2
- 40,676.29 shares@ US$460.0026.3% of flowcommon stockSEC:0001400964-24-000005:2
- 310.89 shares0common stockSEC:0001400964-24-000004:0
- 310.89 shares@ US$452.430.2% of flowcommon stockSEC:0001400964-24-000003:1
- 310.89 shares@ US$452.430.1% of flowcommon stockSEC:0001221109-24-000001:1
- 310.89 shares0common stockSEC:0001221109-24-000001:0
- 310.89 shares0common stockSEC:0001400964-24-000003:0
- 45 shares@ US$440.8027.1% of flowcommon stockSEC:0001963160-24-000002:1
- 163 shares0common stockSEC:0001963160-24-000002:0
- 300 shares@ US$319.6811.8% of flowcommon stockSEC:0001700366-23-000006:0Canonical exit: 29 Feb 2024 (T+90)
- 300 shares@ US$300.000.3% of flowcommon stockSEC:0001400964-23-000003:0Canonical exit: 14 Feb 2024 (T+90)
- 186 shares@ US$444.0350.3% of flowcommon stockSEC:0001920839-23-000002:0
- 200 shares@ US$523.3512.8% of flowcommon stockSEC:0001700366-23-000003:0
- 310.89 shares@ US$565.700.2% of flowcommon stockSEC:0001221109-23-000002:1
- 310.89 shares@ US$565.700.6% of flowcommon stockSEC:0001400964-23-000002:1
- 310.89 shares0common stockSEC:0001221109-23-000002:0
25 of 546 declarations
About Atrion Corp
Atrion Corp. (ticker: ATRI) is a United States-based company listed on the NASDAQ market. It is best known as a specialized manufacturer of products used primarily in medical applications, with a business model centered on engineered components and niche devices rather than mass-market healthcare products. For French, Belgian, and Swiss investors, Atrion stands out as a focused, high-specification industrial healthcare supplier with exposure to hospital, clinical, and home-care use cases.
The company was founded in the mid-20th century and has built its identity around technical manufacturing, proprietary product design, and long-standing customer relationships. Atrion is headquartered in Allen, Texas, United States. Its operating model emphasizes in-house manufacturing, quality control, and engineering expertise in regulated environments. That industrial base is strategically important: in a business where reliability, precision, and compliance matter, manufacturing know-how can be a key competitive moat.
Read moreShow less
Atrion’s core business includes fluid delivery products, which are designed to precisely fill, hold, release, or remove controlled amounts of fluids or gases. These products serve applications such as anesthesia, oncology, intubation, intravenous therapy, catheters, and related hospital uses. The company also manufactures products that support infection control in hospital and home-healthcare settings, as well as selected ophthalmic products. In addition, Atrion has historically highlighted highly specialized devices used in marine and aviation safety applications, reinforcing its profile as a niche engineering business.
From a competitive standpoint, Atrion is not a broad-line medical device giant; it is a specialist. Its competitive position is built on proprietary designs, technical capabilities, and the ability to serve demanding customers with tailored solutions. This can support pricing discipline and customer stickiness, but it also means the company is more exposed to niche end markets, manufacturing execution, and regulatory quality standards than a diversified medtech peer.
Geographically, Atrion remains anchored in the United States, while serving customers through an international manufacturing and distribution footprint. Recent SEC-disclosed information indicates continued focus on existing product lines, operational continuity, and manufacturing efficiency rather than transformative expansion. The company’s business profile therefore fits a defensive, specialized healthcare-industrial investment case: modest scale, technical differentiation, and a portfolio of products serving essential but narrowly defined markets.
